Trial reportThe AAPS journal2017
Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.
Trial report in The AAPS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Effect of hydrocortisone-fludrocortisone combination on mortality in septic shock: a systematic review and meta-analysis.Infection · 2025Pooled it
- Fludrocortisone dose-response relationship in septic shock: a randomised phase II trial.Intensive care medicine · 2024Trial
- Mineralocorticoid magic? Evaluating fludrocortisone in septic shock.British journal of clinical pharmacology · 2026Review
- Protective effect of Spirulina andOpen veterinary journal · 2025Article
- Successful Management of Cerebral Salt-Wasting Syndrome in a Child With Epileptic Encephalopathy: A Case Report.Clinical case reports · 2025Article
- Update on the Treatment of Autonomic Disorders.Current treatment options in neurology · 2025Article
- Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.Endocrine connections · 2023Article
- Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children.CPT: pharmacometrics & systems pharmacology · 2023Article
- Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension.Current neurology and neuroscience reports · 2021Review
- Effects of dexamethasone and hydrocortisone on rocuroniuminduced neuromuscular blockade and reversal by sugammadex in phrenic nerve-hemidiaphragm rat model.Korean journal of anesthesiology · 2019Article
- Use of fludrocortisone for intradialytic hypotension.Kidney research and clinical practice · 2018Article
- Immune Effects of Corticosteroids in Sepsis.Frontiers in immunology · 2018Review
- Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta-analysis.Acute medicine & surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed at describing the pharmacokinetics and the concentration-effect relationships of fludrocortisone and hydrocortisone on urinary sodium/potassium excretion in healthy volunteers. This was a placebo-controlled, randomized, double blind, crossover study, of oral fludrocortisone and intravenous hydrocortisone, given alone or in combination, in 12 healthy male volunteers. Nonlinear mixed-effects modeling was used to describe the pharmacokinetics and pharmacokinetic-pharmacodynamic relationships on urinary sodium/potassium ratio for each drug. A one-compartment model was used to describe fludrocortisone and hydrocortisone pharmacokinetics. Mean plasma half-life was 1.40 h (95%CI [0.80;2.10]) for fludrocortisone and 2.10 h (95%CI [1.78;2.40]) for hydrocortisone. Clearance was 40.8 L/h (95%CI [33.6;48]) for fludrocortisone and 30 L/h (95%CI [25.3;34.7]) for hydrocortisone. An indirect response model was used to describe effects on urinary sodium/potassium ratio. Fludrocortisone plasma concentrations showed a wider inter-individual dispersion than hydrocortisone plasma concentrations. Urinary sodium/potassium ratio variability was also higher with fludrocortisone as compared to hydrocortisone. The plasma concentration of drug producing 50% of maximal inhibition of urinary sodium/potassium (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.